Kirkland & Ellis Advises Ally Bridge Group on Privatization Offer for Hong Kong-listed Shandong Luoxin Pharmaceutical Group
Kirkland & Ellis is advising Ally Bridge Group, as a joint offeror with a consortium established by an affiliate of the target company’s controlling shareholder and GL Capital Group, in its proposed HK$2.34 billion (US$300 million) privatization offer for the H shares of Shandong Luoxin Pharmaceutical Group (HKSE: 8058) by way of a voluntary conditional cash offer. The transaction is conditional on, amongst other things, Shandong Luoxin’s shareholders approval.